Lee, K.-J.; Singh, N.; Bizuneh, M.; Kim, N.-H.; Kim, H.S.; Kim, Y.; Lee, J.-J.; Kim, J.H.; Kim, J.; Jeong, S.Y.;
et al. miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53. J. Pers. Med. 2023, 13, 1302.
https://doi.org/10.3390/jpm13091302
AMA Style
Lee K-J, Singh N, Bizuneh M, Kim N-H, Kim HS, Kim Y, Lee J-J, Kim JH, Kim J, Jeong SY,
et al. miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53. Journal of Personalized Medicine. 2023; 13(9):1302.
https://doi.org/10.3390/jpm13091302
Chicago/Turabian Style
Lee, Kyung-Jun, Nitya Singh, Michael Bizuneh, Nam-Hyeok Kim, Hyeong Su Kim, Youngmi Kim, Jae-Jun Lee, Jung Han Kim, Jiye Kim, Soo Young Jeong,
and et al. 2023. "miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53" Journal of Personalized Medicine 13, no. 9: 1302.
https://doi.org/10.3390/jpm13091302
APA Style
Lee, K.-J., Singh, N., Bizuneh, M., Kim, N.-H., Kim, H. S., Kim, Y., Lee, J.-J., Kim, J. H., Kim, J., Jeong, S. Y., Cho, H.-Y., & Park, S. T.
(2023). miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53. Journal of Personalized Medicine, 13(9), 1302.
https://doi.org/10.3390/jpm13091302